Applying AI for earlier diagnosis and ‘enriched populations’​
PHASE II | AI, is collaborating with multi-stakeholder consortiums encompassing life science companies, healthcare authorities, healthcare professionals and tech providers to deploy AI-powered predictive analytics & machine learning solutions that can detect disease early – up to five years before it develops. ​
​
Identification of sub-clinical disease enables HCPs to intervene with therapies to prevent progression and can support life science companies identify ‘enriched patient populations’ for their clinical trials to optimize the chances of observing significant effects of a treatment by focusing on a group of individuals most likely to experience those effects.​
​
Contact us for further information about using AI to detect disease earlier
